Trends in antifungal use among hospitalized patients in the USA, 2018–23
Journal of Antimicrobial Chemotherapy · 03.10.2025 · 80 (10) · 2659-2664
DOI: 10.1093/jac/dkaf269 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 11.08.2025. Verfasst von Dallas J Smith und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-11, Atlanta, GA 30329, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Mycoses, Drug Utilization. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background and objectives Fungal infections cause substantial morbidity and mortality. Monitoring antifungal use is a foundational aspect of antifungal stewardship, particularly as new disease-causing fungi emerge and antifungal resistance spreads. We assessed recent patterns in systemic antifungal medication use among hospitalized patients within a diverse convenience sample of academic medical centres and community hospitals in the USA.
Methods
We conducted a multicentre retrospective cohort study using the Vizient® Clinical Data Base. We selected hospitalized patients who received ≥1 dose of systemic antifungal medication during 2018–23 and assessed antifungal days of therapy (DOT) per 1000 patient days. We stratified antifungal DOT by National Comprehensive Cancer Network (NCCN) cancer centre status to compare antifungal use at hospitals with an NCCN-designated cancer centre—some of which also include a main academic medical centre and non-cancer service lines—versus hospitals without an NCCN-designated cancer centre.
Results
Among 39 956 873 discharges from 412 hospitals, the proportion of patients who received any systemic antifungal was 4.5%; azoles (3.8%) were the most common antifungal class, followed by echinocandins (0.9%). Overall antifungal DOT were 53.7 per 1000 patient days (114.5 among 25 NCCN hospitals and 43.2 among 387 non-NCCN hospitals).
Conclusions
Substantial antifungal use occurs among hospitalized patients, particularly among those with cancer. The growing population susceptible to fungal infections (e.g. transplants, cancer and other immunosuppressing conditions) warrants consideration of antifungal stewardship and evaluation of appropriateness of antifungal use in the context of increasing resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-11, Atlanta, GA 30329, USA.
- Vizient Inc., Irving, TX, USA.
- Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID-Profile: Dallas J Smith, Kaitlin Benedict
Zitieren
APA
Smith, D. J., Murphy, H. R., Benedict, K., Dailey Garnes, N. J. M., Vuong, N. N., Harris, A. H., & John, T. M. (2025). Trends in antifungal use among hospitalized patients in the USA, 2018–23. Journal of Antimicrobial Chemotherapy, 80(10), 2659-2664. https://doi.org/10.1093/jac/dkaf269
Vancouver
Smith DJ, Murphy HR, Benedict K, Dailey Garnes NJM, Vuong NN, Harris AH, et al. Trends in antifungal use among hospitalized patients in the USA, 2018–23. Journal of Antimicrobial Chemotherapy. 2025;80(10):2659-2664. doi:10.1093/jac/dkaf269
BibTeX
@article{Smith2025,
author = {Smith, Dallas J and Murphy, Hannah R and Benedict, Kaitlin and Dailey Garnes, Natalie J M and Vuong, Nancy N and Harris, Alyssa H and John, Teny M},
title = {Trends in antifungal use among hospitalized patients in the USA, 2018–23},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {10},
pages = {2659--2664},
doi = {10.1093/jac/dkaf269}
}
EUVIMED